Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
Would you give adjuvant chemotherapy for adenoid cystic carcinoma of breast that is low ER positive, early stage, node negative?
Would you use oncotype to guide your decision?
Answer from: Medical Oncologist at Academic Institution
Simple answer: No.
Sign in or Register to read more
3431
Related Questions
What is the goal of estradiol levels on ovarian suppression and AI for breast cancer?
Is it okay to send an Oncotype solely for prognostic purposes to a patient who doesn't want chemotherapy or an elderly patient with poor PS?
Does the degree of hormone receptor positivity influence your decision to perform Oncotype testing?
Would you consider offering adjuvant Olaparib to a patient with early stage triple negative breast cancer, cT3N0, ypT1aN0, with BRCA VUS who has residual disease after neoadjuvant KEYNOTE-522 regimen?
Would history of breast cancer deter you from using ospemifene for severe vaginal dryness/dyspareunia?
When should paclitaxel (or other chemo) be discontinued in de novo metastatic triple negative breast cancer with high PDL1 in favor of continuing pembrolizumab alone with good treatment response?
What disease characteristics will guide your choice of alpelisib plus fulvestrant (per SOLAR-1) versus capivasertib plus fulvestrant (per CAPItello-291) in PIK3CA mutated advanced ER+/HER2- breast cancer after progression on 1L ET regimen, given both are now approved in this population?
How would you approach a postmenopausal patient on Letrozole who developed cataracts within the first six months of treatment?
How do you treat 1L metastatic triple negative breast cancer with somatic BRCA1/2 mutation, CPS <10?
Is there safety data regarding the use of hormonal IUDs in patients with atypical ductal hyperplasia and other high risk, non-malignant breast lesions?